PPIs (Protein-Protein Interactions) that are part of costimulatory and coinhibitory (immune checkpoint) signaling play a crucial role in immune responses and serve as critical therapeutic targets for immunomodulation. There are already a number of biologics targeting these targets that are being used in the treatment of cancer (ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab) and autoimmune diseases (e.g., abatacept, belatacept, and belimumab). Over the past decade, substantial progress has been made in the development of PPI targets and modulation methods, but further progress remains to be made.
As high-throughput sequencing with genomic and proteomic data has become increasingly available, a growing number of efforts have been directed towards recognizing the role of PPIs in immunoregulation. It remains a challenging task to identify novel protein-protein interactions relating to immunity and/or to identify the underlying mechanisms for these interactions. A growing awareness of PPIs has led to an increase in the demand for immunomodulation. Furthermore, more novel therapies are required for the immunomodulation of disease, such as the use of exogenous molecules, the engineering of living cells, etc. Considering that, this Research Topic aims to bring together leading researchers to exchange and share their findings, opinions, and perspectives on tracking these questions.
Hence, we want to include the following:
(1) Identifying newfound protein-protein interactions related to immunity and/or revealing their mechanisms;
(2) Developing methods to regulate PPIs in various diseases using pharmacological (such as small molecules, peptides, proteins, nucleic acids, and antibodies) and non-pharmacological methods (such as Car-T, Car-NK, engineered cells, and extracellular vesicles);
(3) Using advanced technologies including artificial intelligence (AI), synthetic biology and high-throughput bioinformatics to discover new action modes of immune-related PPIs.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
PPIs (Protein-Protein Interactions) that are part of costimulatory and coinhibitory (immune checkpoint) signaling play a crucial role in immune responses and serve as critical therapeutic targets for immunomodulation. There are already a number of biologics targeting these targets that are being used in the treatment of cancer (ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab) and autoimmune diseases (e.g., abatacept, belatacept, and belimumab). Over the past decade, substantial progress has been made in the development of PPI targets and modulation methods, but further progress remains to be made.
As high-throughput sequencing with genomic and proteomic data has become increasingly available, a growing number of efforts have been directed towards recognizing the role of PPIs in immunoregulation. It remains a challenging task to identify novel protein-protein interactions relating to immunity and/or to identify the underlying mechanisms for these interactions. A growing awareness of PPIs has led to an increase in the demand for immunomodulation. Furthermore, more novel therapies are required for the immunomodulation of disease, such as the use of exogenous molecules, the engineering of living cells, etc. Considering that, this Research Topic aims to bring together leading researchers to exchange and share their findings, opinions, and perspectives on tracking these questions.
Hence, we want to include the following:
(1) Identifying newfound protein-protein interactions related to immunity and/or revealing their mechanisms;
(2) Developing methods to regulate PPIs in various diseases using pharmacological (such as small molecules, peptides, proteins, nucleic acids, and antibodies) and non-pharmacological methods (such as Car-T, Car-NK, engineered cells, and extracellular vesicles);
(3) Using advanced technologies including artificial intelligence (AI), synthetic biology and high-throughput bioinformatics to discover new action modes of immune-related PPIs.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
